However, few reports have described the clinical characteristics and response to EGFR-TKIs of NSCLC patients with concomitant mutations of 19Del and L858R, and case numbers have been limited [3, 8, 9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.